Boyd Watterson Asset Management LLC OH Has $1.18 Million Stake in Pfizer Inc. (NYSE:PFE)

Boyd Watterson Asset Management LLC OH decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 33.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,796 shares of the biopharmaceutical company’s stock after selling 20,052 shares during the quarter. Boyd Watterson Asset Management LLC OH’s holdings in Pfizer were worth $1,175,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley raised its position in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Pfizer by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after purchasing an additional 5,185,453 shares during the last quarter. Invesco Ltd. raised its position in Pfizer by 30.9% during the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after purchasing an additional 5,678,004 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Pfizer by 0.6% during the 3rd quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after purchasing an additional 101,256 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Up 0.6 %

PFE stock traded up $0.14 during mid-day trading on Friday, reaching $25.40. 46,526,457 shares of the company traded hands, compared to its average volume of 34,120,812. The stock has a market cap of $143.83 billion, a price-to-earnings ratio of 70.50, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The firm’s 50 day moving average price is $26.96 and its 200 day moving average price is $28.42.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s payout ratio is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.